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Adrenocortical cancer is an extremely rare tumor presenting with extensive locoregional spread at the time of diagnosis. Due to the 
diagnostic difficulties preoperatively and a lack of effective treatment options, patients have poor prognosis. Patients succumb 
to metastases within a couple of months. Only 20 cases have been so far reported in the literature with a medium disease-free 
survival up to 2 years. We present a case of a locoregional recurrence of adrenocortical cancer 18 years after left adrenalectomy.
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Adrenocortical carcinomas (ACC) are rare neo­
plasms that occur in 0.5–2 cases per million people 
per year [2, 11]. ACC has a female predominance [20]. 
Adrenal masses are usually found incidentally dur­
ing radiological examinations performed for indica­
tions other than adrenal diseases. Incidental adrenal 
masses are reported as 8.7% of the adrenal cancer 
cases [10]. In 50% cases tumor cells release one of ad­
renocortical gland hormones, what makes for special 
manifestations of this pathology including virilism 
and clinical symptoms of hyperadrenalismus. In most 
cases ACC are exceeding 20 cm in diameter and have 
a strong tendency to invade the adrenal vein, vena 
cava. Metastases to regional and periaortic nodes are 
common, as is distant hematogenous spread to the 
lungs and other viscera. The median survival is about 
2 years [11]. ACC is a very rare malignant tumor and 
to date there were only 20 cases reported in the lite­
rature and to the best of our knowledge there have 
been no cases with the disease­free survival more 
than 5 years [9, 10, 12, 18]. The majority of those pa­
tients succumbed to disease within a year due to local 
recurrence or metastases [20]. Here, we report about 
a patient who was admitted with left­sided adrenal 
mass and diagnosed with recurrence of adrenal corti­
cal carcinoma after left adrenalectomy 18 years ago.
CASE REPORT
A 35­year­old female was admitted to the surgical 
department of State Scientific Institution “Scientific­
Practical Centre of Preventive and Clinical Medicine”, 
State Administration of Affairs, Kyiv, Ukraine, due 
a headache, and hypertension crisis resistant to medi­
cal therapy. She had a remarkable medical history: 
18 years ago she underwent left adrenalectomy for 
an ACC. The tumor exceeded 18 cm in diameter. 
Histopathological examination of the adrenalectomy 
specimen revealed left high­grade adrenal carci­
noma. The final pathological diagnosis was left ACC 
pT3N0M0, stage III, 3rd clinical group. After the surgery 
the patient quarterly underwent follow­up for cancer, 
urine steroids tests, abdominal radiography and ultra­
sound, magnetic resonance imaging (MRI). She was 
observed by oncologist, gynecologist, endocrinologist 
and was prescribed the substitution cortisol therapy. 
The patient became pregnant on the 12th year post­
operatively. After the delivery she discontinued all the 
recommendations and prescriptions because of good 
state of health. She started feeling worse 18 years 
after the left adrenalectomy, therefore she consulted 
the same doctor.
Upon physical examination blood pressure was 
220/130 mm Hg and her pulse was 88/min. Her 
body mass index was 35.1. The signs and symptoms 
of adrenal hormone oversecretion were proven with 
laboratory oversecretion of 11­deoxycorticosterone 
and dehydroepiandrosterone (DHEA). Serum cortisol 
and the aldosterone to renin ratio were normal. Ultra­
sonography showed heterogeneous and hypoechoic 
lesion of left arenal gland 6.3 × 5.4 × 2.9 cm with 
non­defined borders (Fig. 1). Abdominal computed 
tomography (CT) scan with intravenous contrast 
showed 7.1 × 5.3 × 3.8 cm soft­tissue mass with ir­
regular borders in the left adrenal bed with abnormal 
postoperative cellular tissue. Vena renalis sinistra 
was strangulated by a neoplasm, luminal narrowing 
is 0.5 cm (Fig. 2). 
Fig. 1. Results of ultrasound of the adrenal bed
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Fig. 2. CT of abdomen showing large left­sided adrenal mass (arrow)
Mammography, upper gastrointestinal system en­
doscopy, thorax CT, liver function tests including ALT 
and AST were performed to exclude metastasis from 
other organs to adrenals, which gave normal results.
We set up the following preoperative diagnosis: 
Ca suprarenal gland sinister T3NxMx stage III. State 
post adrenalectomy (1999). Progression of the dis­
ease: relapse of adrenal cortical carcinoma.
The patient went on to have a total resection of lo­
cal relapse of adrenal tumor and nephrectomy for the 
underlying lesion. 
On gross examination specimen removed from the 
bed of the left adrenal measured 6 × 5 × 3 cm (Fig. 3). 
The mass was found to be a grey­yellow­pink tumor with 
a humpy surface. On cut surface, there are green­grey, 
yellow­grey colored areas with focuses of malaxing and 
necrosis within the mass. The left kidney and vena renalis 
sinistra were adhered to tumor and involved in tumorous 
mass. The interface between the kidney and the mass 
was examined carefully by close serial sectioning. On the 
excision axis, the tumor spreads to the vena renalis wall.
Fig. 3. Specimen of the mass removed from the bed of the left 
adrenal gland
On microscopic examination the tumor of left retro­
peritoneal space showed atypical cells with evidence 
foci of necrosis (Fig. 4). There was hyperchromatic 
cells with epithelial and spindle cell morphology, and 
nuclear atypia. It could point to discomplectation 
of structure — the widely­spread parts of carcinoma 
do not contain stromal cells. Tumor spreads to the 
adventitia and media of vena renalis wall. 
Based on the histologic profile, the tumor was 
diagnosed as high­grade ACC, with necrosis areas, 
invasion of left renal vein. 
At the time of writing, 11 months postoperatively, 
the patient remained alive and underwent the follow­
up visits to the endocrine surgeon, oncologist and 
gynecologist.
DISCuSSION
ACC is a rare and highly malignant endocrine 
neoplasm accounting for an estimated 0.02% of all 
cancer cases [5, 6]. The majority of adrenal tumors are 
mostly sporadic and unilateral but some of them are 
associated with Li — Fraumeni syndrome, type­1 mul­
tiple endocrine neoplasia, Beckwith — Wiedemann 
syndrome and Carney complex [10, 13]. ACC typically 
metastases to the lung, liver, peritoneum and pleura, 
lymph nodes and bones [11, 20]. Prognosis is conside­
rably poor, and the 5­year overall survival rate of ACC 
is less than 30% [3]. Even with favorably performed 
radical resections, the majority of patients succumb 
to local recurrence or de novo metastases [8].
Although remarkable medical history of left ad­
renalectomy 18 years ago, we initially carried out 
a diagnostic workup to exclude metastasis from 
extra­adrenal organs and suspected the potentially 
malignant adrenal incidentaloma. The primary can­
cers that mostly spread to the adrenal gland are those 
of kidneys, lungs, colon, liver and breast [8]. In this 
context we performed mammography, colonoscopy, 
upper gastrointestinal system endoscopy, thorax CT, 
all of which were normal. The initial diagnosis we could 
Fig. 4. Histopathology section showing extensive necrosis of tu­
mor. Hematoxylin­eosin, original magnification, × 200
Fig. 5. Histopathology section showing cells with epithelial and 
spindle cell morphology, and nuclear atypia.  Hematoxylin­eosin, 
original magnification, × 400
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make was the recurrence, local relapse of adrenal 
cortical carcinoma. According to the recent guidelines 
adrenal biopsy is not an option for the patients with 
such an initial diagnosis because of risk of tumor dis­
semination [6]. Postoperative histopathological exami­
nation of the total removal of local relapse of adrenal 
tumor specimens revealed left­sided high­grade ACC 
with vena renalis sinistra invasion. 
Based on the data collected from the previous 
cases ACC is more frequent in women than in men 
(ratio 1.5:1) [6]. In twelve cases reported in the world 
literature the patients died within 2 days to 30 months 
after the initial diagnosis [10, 20]. Our case was a mid­
dle­aged woman who survived 18 years after the left 
adrenalectomy performed for ACC. At the 11­months 
follow up after the removal of local relapse of ACC the 
patient was free of disease progression.
ACCs tend to be aggressive, and patients often 
present with extensive locoregional spread at diag­
nosis [20]. A detailed preoperative endocrine assess­
ment is essential to establish the origin of the tumor 
that is why in all cases of adrenal mass a comprehen­
sive hormonal analysis is strongly recommended [2]. 
Moreover, urine steroid metabolomics revealed an ear­
ly­stage steroidogenesis in ACC that performed well 
in differentiating malignant neoplasms from adrenal 
adenomas [1]. Cases of ACC with adrenal hormone 
production have been reported previously; there was 
a significant urine steroids overproduction in our case 
as well [4]. Previous studies demonstrated that CT and 
MRI are effective modalities for diagnosis and tumor 
location confirmation [6, 7, 20].
After surgical excision, including complete meta­
static resection, adjuvant chemotherapy is indicated. 
Our patient avoided receiving any chemotherapy. 
But there are some data with controversial effects 
of chemotherapy postoperatively [16, 20]. Additional 
research is required in order to confirm the significant 
effect of chemotherapy. Mitotane induces adrenal 
cortex degeneration and necrosis, and in combination 
with chemotherapy tends to be more effective than 
chemotherapy alone [17].
ACC is rare tumor with an aggressive and unpre­
dictable behavior. Due the diagnostic difficulties pre­
operatively and a lack of effective treatment options, 
patients have poor prognosis. Mostly, only postopera­
tive immunohistochemical examination may provide 
a definitive diagnosis. The only effective option for 
tumors at present is adrenal surgery. In case of ad­
vanced adrenal cortex cancer adjuvant chemotherapy 
is considered ineffective. To the best of our knowledge, 
our case is the first case of 18­years surveillance after 
the adrenalectomy because of ACC reported in the 
literature [10, 14, 15, 19, 20]. The possible diagnosis 
of ACC should be considered during the management 
of adrenal masses. Therefore, additional research 
is required in order to explore targeted therapy for 
management of advanced and metastatic ACC.
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